NattoPharma (NATTO)

[TekBot]

1 Expiry of the unconditional offer to acquire up to 11.0% of the shares in NattoPharma ASA and withdrawal of the intention to make a voluntary offer

NOT FOR DISTRIBITION IN OR INTO THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL

Reference is made to the stock exchange announcement on 28 May 2020 where Kappa Bioscience AS (“Kappa”) announced an offer to acquire up to 11% of the shares in NattoPharma ASA (“NattoPharma”), at a price of NOK 12.75 per share (the “Offer”), and the stock exchange announcement on 12 June 2020 where the offer period was extended until 26 June 2020. Kappa has resolved not to extend the offer period and the Offer expires today at CET 24.00.
…

Vis børsmeldingen

On 28 May Kappa further announced an intention to make a voluntary offer to acquire all the outstanding shares in NattoPharma at an offer price of NOK 12.75 per share, provided that certain conditions for launch of the voluntary offer, including access to due diligence, were fulfilled. NattoPharma announced on 29 May 2020 that it currently was of the view that it would not give Kappa access to do a due diligence, and Kappa has consequently resolved to withdraw its intention to make a voluntary offer.

Kappa continues to believe there is a strong strategic, commercial and financial rationale for a combination with NattoPharma, but notes that NattoPharma and the capital market currently have a different view on the valuation of NattoPharma than Kappa.

About Kappa Bioscience AS

Kappa Bioscience AS is a Norwegian entity founded in December 2006. Utilizing advanced production technology based on a strong patent portfolio, Kappa has secured global leadership in the production and development of vitamin K2, which is one of the fastest-growing health ingredients worldwide. Kappa is currently the leading vendor of vitamin K2 for use in various formulations, and Kappa’s leadership in the vitamin K2 market is further exemplified by its recent patent expansion in the production of vitamin K2 as pure MK-7 (menaquinone-7). While vitamin K2 provides the cornerstone for Kappa’s business, Kappa also offers a range of bone and heart health category ingredients in several forms and concentrations. A key objective going forward is to make vitamin K2 accessible for the global food supplement and fortified food market. Kappa will continue to serve the market with pure and stable forms of MK-7 products. With regulatory approvals in leading markets, including US self-affirmed GRAS and an NDIN, Kappa’s vitamin K2 MK-7 can be used in most applications, also in conventional foods.

Advisers and contact

Carnegie AS is acting as financial advisor and Advokatfirmaet Wiersholm AS is acting as legal advisor to Kappa in connection with the Voluntary Offer and the Offer.
For additional information please contact:
Egil Greve, President & CEO Kappa Bioscience AS, +47 95 10 95 65, egil.greve@kappabio.com
Stefan Schander Slemdal, Carnegie AS, +47 40 64 04 26, stefan.slemdal@carnegie.no

Kilde

[vandregutten]

Helt utroligt at de har klart at lure til sig 1 mill aksjer. Det er en gal verden.

[rokky]

Litt av et kunststykke å selge dem 10k aksjer til 12,75 per stk., når aksjen har tradet over 15 kroner i lang tid. Veldedighet?

[FeitaInc]

Hva…? Har noen solgt aksjer til de til 12.75kr?

[Savepig]

Veldig forvirret price action i aksjen. Men er jo enorm fordel for oss som er nye inne som eiere at vi har kunnet følge denne tråden over lang tid

[holmes]

Kappa Bioscience AS has today in connection with the unconditional offer expiring today purchased 10,158 shares in NattoPharma ASA at a price of NOK 12.75 per s

[nofun]

Du som solgte til de ?

[holmes]

Haha nei

[TekBot]

UPDATE ON STRATEGIC REVIEW

Oslo, Norway (26 June 2020) - Reference is made to the stock exchange notice
issued on 26 June 2020 from Kappa Bioscience AS (“Kappa”).

…

Vis børsmeldingen

As communicated in the stock exchange notice dated 2 June 2020, NattoPharma ASA
(“NattoPharma” or the “Company”) has engaged ABG Sundal Collier ASA to conduct a
strategic review of the Company. The Board of NattoPharma remain of the firm
view that the now withdrawn offer from Kappa did substantially undervalue the
Company’s leading market position and continued growth prospects.

The strategic review is ongoing, considering various alternatives to maximize
shareholder value. NattoPharma will provide further updates to its shareholders
in due course.

---

For more information, please contact:

Robert Schrama, CFO

E-mail: robert.schrama@nattopharma.com

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities

Kilde

[Hypergris]

De driver gjøn med selskapet og aksjonærene.

«Se noen mener selskapet er verdt kun 12,75kr, dere andre bør også selge til samme pris»

https://www.urbandictionary.com/define.php?term=Kappa&amp=true&defid=7927027

[holmes]

Haha et passende navn har de funnet seg i hvert fall

represents sarcasm, irony, puns, jokes, and trolls alike.

[holmes]

Flere luringer som tar det gode tilbudet?

• • 25 000 12,75 16:54:50

[holmes]

Er vel bare snakk om dager før denne eksploderer opp nå?

[FeitaInc]

Har vel mer eller mindre stilt megselv det spørsmålet daglig de siste årene.

[holmes]

Fundamental sett ja, helt enig, men nå virker det som om vi også har litt moment med oss endelig.

[FeitaInc]

Se der ja. Grei avslutning på dagen.

[Savepig]

Deilig å være inne, utrolig spennende.

[TekBot]

KAYDENCE PHARMA UPDATE

Oslo, Norway (30 June 2020)

At the Annual General Meeting (“AGM”) today of Kaydence Pharma AS ("Kaydence
…

Vis børsmeldingen

Pharma") it has been decided that NattoPharma ASA (“NattoPharma”) will convert
NOK 4 million of its loans to equity in Kaydence Pharma. The loan will be
converted at NOK 5 per share giving NattoPharma a total number of 3 000 000
shares representing a 54.15% interest as at 30 June 2020. Following the
conversion, NattoPharma´s loan to Kaydence Pharma is NOK 51 million.

Further the AGM decided that the Board of Kaydence Pharma has been replaced with
Kjetil Ramsøy as Chairman of the Board and Robert Schrama as Director.

“The increase in ownership further secures NattoPharma’s claim patents and is
therefore in line with our strategy”, says Mr. Ramsøy. Erik Flatmark, the former
Chairman of Kaydence Pharma, says: “I am happy that NattoPharma has taken this
step in further securing control of Kaydence after the activities had been
suspended earlier this year.”

Following these two decisions by the AGM, NattoPharma will have a controlling
interest and Kaydence Pharma will be part of the consolidated accounts of
NattoPharma going forward. The impact of the conversion will be reflected in the
Q2 financials.

---

For more information, please contact:

Robert Schrama, CFO

E-mail: robert.schrama@nattopharma.com

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities

Kilde

[anon80503862]

Ødelegger litt kvartalsrapporter framover ?

[holmes]

Ikke nødvendigvis, Lån blir EK